Introduction：Basic information about CAS 63074-08-8|Terazosin hydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Terazosin hydrochloride |
|---|
| CAS Number | 63074-08-8 | Molecular Weight | 423.89 |
|---|
| Density | 1.3±0.1 g/cm3 | Boiling Point | 664.5±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C19H26ClN5O4 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 355.7±34.3 °C |
|---|
Names
| Name | Terazosin hydrochloride |
|---|
| Synonym | More Synonyms |
|---|
Terazosin hydrochloride BiologicalActivity
| Description | Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3]. |
|---|
| Related Catalog | Research Areas >>EndocrinologySignaling Pathways >>GPCR/G Protein >>Adrenergic ReceptorResearch Areas >>Metabolic Disease |
|---|
| Target | α1-adrenoceptor[1] |
|---|
| In Vitro | Terazosin does not discriminate cloned α1-adrenoceptor subtypes transiently expressed in COS cells[1]. |
|---|
| In Vivo | Terazosin can be used to promote stone discharge in treatment of ureteral stones. Terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm[3]. |
|---|
| References | [1]. Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [2]. Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8. [3]. Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851. |
|---|
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|
| Boiling Point | 664.5±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C19H26ClN5O4 |
|---|
| Molecular Weight | 423.89 |
|---|
| Flash Point | 355.7±34.3 °C |
|---|
| PSA | 103.04000 |
|---|
| LogP | -0.96 |
|---|
| Appearance of Characters | powder,white to off-white |
|---|
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
|---|
| Index of Refraction | 1.636 |
|---|
| InChIKey | IWSWDOUXSCRCKW-UHFFFAOYSA-N |
|---|
| SMILES | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl |
|---|
| Storage condition | Store at RT |
|---|
| Water Solubility | H2O: 25 mg/mL |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- TK8045000
- CHEMICAL NAME :
- Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahyd ro-2-furanyl)carbonyl )-, monohydrochloride
- CAS REGISTRY NUMBER :
- 63074-08-8
- LAST UPDATED :
- 199503
- DATA ITEMS CITED :
- 2
- MOLECULAR FORMULA :
- C19-H25-N5-O4.Cl-H
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 277 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea
- REFERENCE :
- DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 7,435,1984 ** OTHER MULTIPLE DOSE TOXICITY DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 4650 mg/kg/31D-I
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - ptosis Nutritional and Gross Metabolic - body temperature decrease Related to Chronic Data - death
- REFERENCE :
- DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 7,435,1984
|
Safety Information
| Hazard Codes | Xn,Xi |
|---|
| Risk Phrases | 22-36/37/38 |
|---|
| Safety Phrases | 26-36 |
|---|
| WGK Germany | 3 |
|---|
| RTECS | TK8044925 |
|---|
Synonyms
| piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]- |
| Terazosin |
| UNII:8L5014XET7 |
| Vicard |
| Itrin |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone,hydrochloride |
| Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)- |
| Urodie |
| [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)methanone |
| 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine |
| MFCD00467965 |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone |
